Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (231-240 of 269) with videos related to

Pageof 27
Sort By:
JCO Precision Oncology|September 4, 2024
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung CancerYonina R Murciano-Goroff, Angela B-Y Hui, Jose A Araujo Filho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
<i>KRAS</i> <sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung AdenocarcinomaGregory D Jones, Raul Caso, Kay See Tan, et al.
Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Nature Communications|March 19, 2022
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancersEzra Y Rosen, Helen H Won, Youyun Zheng, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
Cancer Discovery|October 2, 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsEmiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Neuro-Oncology|December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumorsFrançois Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Pageof 27

Showing results (231-240 of 269) with videos related to

Sort By:
Pageof 27
JCO Precision Oncology|September 4, 2024
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung CancerYonina R Murciano-Goroff, Angela B-Y Hui, Jose A Araujo Filho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
<i>KRAS</i> <sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung AdenocarcinomaGregory D Jones, Raul Caso, Kay See Tan, et al.
Nature Medicine|August 14, 2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activationEmiliano Cocco, Alison M Schram, Amanda Kulick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Nature Communications|March 19, 2022
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancersEzra Y Rosen, Helen H Won, Youyun Zheng, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
Cancer Discovery|October 2, 2020
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase InhibitorsEmiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, et al.
The New England Journal of Medicine|January 10, 2024
Repotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, D Ross Camidge, Jessica J Lin, et al.
Neuro-Oncology|December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumorsFrançois Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 29, 2020
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesBenjamin J Solomon, Lavinia Tan, Jessica J Lin, et al.
Pageof 27